<DOC>
	<DOCNO>NCT00105521</DOCNO>
	<brief_summary>The purpose study determine Sarizotan HC1 1 mg b.i.d . ( take twice day ) effective treatment dyskinesia associate dopaminergic treatment Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>Sarizotan HCl Patients With Parkinson 's Disease Suffering From Treatment-Associated Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<criteria>The subject outpatient . The subject present diagnosis idiopathic Parkinson 's disease . Prior therapy register Parkinsonian medication allow . ( For female subject ) The subject pregnant lactating . The subject participate another clinical study do within past 30 day . The subject receive neurosurgical intervention relate PD . The subject relevant renal impairment . The subject relevant hepatic impairment . The subject suffering dementia psychiatric illness . The subject history allergic asthma .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Dyskinesia associate dopaminergic treatment</keyword>
</DOC>